Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Altimmune, Inc. on August 21, 2017, to report the closing of a previously announced securities offering. The Company is incorporated in Delaware and maintains its principal executive offices in Gaithersburg, Maryland.
Key Financial Metrics and Transaction Details
- Offering Type: Sale of Series B Convertible Preferred Stock and Warrants.
- Aggregate Offering Price: $14.7 million.
- Net Proceeds: Approximately $13.0 million (after deducting placement agent fees, merger-related fees, and estimated offering expenses).
- Preferred Stock Issued: 15,655.714 shares of Series B Convertible Preferred Stock.
- Conversion Terms: Initially convertible into an aggregate of 5,863,564 shares of Common Stock at an initial conversion price of $2.67 per share.
- Warrants Issued: Warrants to purchase an aggregate of 2,345,427 shares of Common Stock.
- Warrant Terms: Initial exercise price of $2.67 per share; immediately exercisable; expire on August 15, 2022.
- Placement Agent: Piper Jaffray & Co.
Material Changes and Rights Modifications
The Company filed a Certificate of Designations with the Secretary of State of Delaware to establish the rights of the Series B Convertible Preferred Stock. Key provisions include:
- Liquidation Preference: In the event of liquidation, dissolution, or winding up, holders of Preferred Stock are entitled to receive cash, securities, or property equal to the then stated value of the Preferred Stock prior to any distribution to holders of junior securities.
- Dividend Rights: Holders are entitled to dividends if and when declared by the Board. No dividends may be declared on securities ranking junior to or pari passu with the Preferred Stock unless Preferred Stockholders receive a pro rata dividend equal to what they would receive if the stock were converted to Common Stock immediately prior to the dividend.
Outlook, Risks, and Management Commentary
The filing confirms the successful closing of the offering under the Company's existing shelf registration statement on Form S-3. Management noted that additional proceeds may be received if warrant holders elect to exercise the warrants by paying the exercise price in cash. The filing does not provide specific forward-looking guidance regarding revenue, profit, or operational milestones beyond the capital raise.
Key Facts for Investor Verification
- Verify the exact net proceeds of $13.0 million against the gross offering price of $14.7 million to understand the total cost of capital raised.
- Review the Certificate of Designations (Exhibit 3.1) for specific limitations on conversion and any anti-dilution provisions not detailed in the summary.
- Monitor the potential dilution impact of the 5,863,564 shares underlying the Preferred Stock and the 2,345,427 shares underlying the Warrants.
- Confirm the status of the "additional fee related to our completed merger" mentioned in the expense deduction to understand historical capital structure obligations.